BS_T0RKFEKR
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- age_years
- 14.375
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.628
- IL6_JAK_STAT3_SIGNALING+0.618
- ALLOGRAFT_REJECTION+0.611
- PROTEIN_SECRETION+0.591
- INFLAMMATORY_RESPONSE+0.575
- INTERFERON_GAMMA_RESPONSE+0.554
- ANDROGEN_RESPONSE+0.550
- MTORC1_SIGNALING+0.537
- HYPOXIA+0.526
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.519
Top 10 suppressed
- G2M_CHECKPOINT-0.366
- E2F_TARGETS-0.343
- WNT_BETA_CATENIN_SIGNALING-0.307
- MYC_TARGETS_V2-0.263
- MITOTIC_SPINDLE-0.242
- SPERMATOGENESIS-0.209
- HEDGEHOG_SIGNALING-0.164
- PANCREAS_BETA_CELLS-0.110
- KRAS_SIGNALING_DN-0.070
- DNA_REPAIR-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031285_D1.RNA-Seq | EPN | EPN Tumor | 0.948 |
| 2 | BS_VARR255N | pilocytic astrocytoma | — | 0.948 |
| 3 | BS_1TPWFSK6 | subependymal giant cell astrocytoma(SEGA) | — | 0.933 |
| 4 | BS_42Y3YANN | pilocytic astrocytoma | — | 0.929 |
| 5 | BS_SQX5E15Z | pilocytic astrocytoma | — | 0.926 |
| 6 | 53D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D | — | — | 0.925 |
| 7 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.924 |
| 8 | BS_KF0ZXDER | Meningioma | — | 0.922 |
| 9 | BS_X16PENSA | pilocytic astrocytoma | — | 0.920 |
| 10 | BS_VW85Q4XJ | low-grade glioma | — | 0.920 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.628 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.618 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.611 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.591 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.575 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.554 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.550 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.537 | Inavolisib | — uncovered |
| HYPOXIA | 0.526 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.519 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| COMPLEMENT | 0.485 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.484 | Inavolisib | — uncovered |
| COAGULATION | 0.478 | Binimetinib | — uncovered |
| P53_PATHWAY | 0.475 | Idelalisib | — uncovered |
| APOPTOSIS | 0.466 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.463 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.444 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.444 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.417 | Inavolisib | — uncovered |